Pacific Biosc Stock Price, News & Analysis

PacBio (Nasdaq: PACB) has announced the inclusion of its Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. This program recognizes instruments and workflows compatible with 10x Genomics' products and applications, expanding sequencing solutions for researchers worldwide.

The Onso platform, known for its exceptional accuracy in short-read sequencing, aligns well with 10x Genomics' tools for single-cell and spatial biology applications. It joins PacBio's MAS-seq long read RNA sequencing solution in the program, as part of PacBio's effort to provide integrated workflows for genomics and transcriptomics research.

Key benefits of this collaboration include:

• Streamlined workflows combining PacBio's Onso platform with 10x Genomics' technologies
• Compatibility with 10x Genomics' Single Cell 3' v3.1 assay
• Enhanced data quality and efficiency in research
• Unmatched sequencing accuracy from PacBio's Onso platform

PacBio (NASDAQ: PACB) has announced a Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to accelerate cancer research using PacBio's advanced sequencing technologies. The collaboration will focus on profiling prevalent cancers in Asia using the Onso short-read sequencing system and Kinnex long-read sequencing kit, with emphasis on single-cell RNA sequencing.

The Onso platform, known for its exceptional accuracy, will be used to detect clinically relevant mutations across various cancer types. PacBio's authorized channel partner, DKSH, has installed the Onso platform at the Cancer Discovery Hub in NCCS. This collaboration aims to benefit Singapore and provide access to cutting-edge technology for the broader research community in Asia.

The integration of Onso for short reads and Revio for long reads will enable comprehensive multi-omics studies, offering new possibilities for precision oncology. This initiative combines short-read and long-read sequencing to explore the genomic complexities of cancers prevalent in Asia, with the ultimate goal of improving tailored diagnostic and treatment options for patients.

PacBio (NASDAQ: PACB) has announced its upcoming third quarter 2024 financial results conference call, scheduled for Thursday, November 7, 2024, at 4:30 pm Eastern Time (1:30 pm Pacific Time). Investors and interested parties can access the webcast through PacBio's investor relations website at https://investor.pacificbiosciences.com/.

For those preferring a dial-in option, the following numbers are provided:

• Toll-free: 1-888-349-0136
• International: 1-412-317-0459

Participants using the dial-in option are advised to join the call ten minutes before the start time and ask to join the 'PacBio Q3 Earnings Call'. A replay of the webcast will be available on the company's investor relations website after the call.

PacBio, A*STAR, and Macrogen have opened a state-of-the-art joint laboratory at A*STAR Genome Institute of Singapore (GIS) in Singapore. This facility will provide local researchers access to cutting-edge long-read sequencing technology, marking a significant milestone for HiFi long-read sequencing applications in precision medicine, population genomics, and health and disease biology in Southeast Asia.

The lab will house two PacBio Revio systems, known for their scalability, high throughput, and ease of use. These systems feature PacBio's proprietary HiFi sequencing technology, offering highly accurate long reads ideal for complex genomic studies and real-time methylation detection. Macrogen will provide streamlined sequencing service support, positioning the lab as a hub for genomics innovation in Singapore.

This collaboration aims to strengthen Singapore's position as a global leader in genomics research, supporting the National Precision Medicine (NPM) long-read sequencing needs and serving as a vital resource for researchers in fields such as population genetics, cancer research, and rare disease studies.

The HiFi Solves Sub-fertility Consortium, led by KK Women's and Children's Hospital in Singapore, is leveraging PacBio HiFi long-read sequencing to improve diagnosis and treatment of subfertility and recurrent pregnancy loss (RPL). This collaboration involves five leading centers across the Asia-Pacific region and utilizes DNAstack's federated data platform for secure, efficient global collaboration.

The consortium aims to revolutionize fertility research by offering a more comprehensive and high-resolution approach to identifying complex chromosomal rearrangements and sub-microscopic abnormalities. This initiative is expected to reduce the 'diagnostic odyssey' for patients and enhance the success of assisted reproductive technologies. The project, spanning through 2025, includes patient recruitment, advanced sequencing, and bioinformatics analysis, with the goal of influencing clinical practices globally.

PacBio (NASDAQ: PACB) has announced a collaboration with the University Hospital of Münster to advance male infertility and rare disease research using long-read whole genome sequencing. The university will deploy PacBio's Revio HiFi sequencing system to obtain highly accurate genomic data, particularly for studying the Y chromosome's role in male infertility. This initiative is part of Germany's GenomeDE Modellvorhaben project and will contribute to the International Male Infertility Genomics Consortium.

The University of Münster aims to sequence 500 patients with male infertility over the next year and conduct trio sequencing of rare disease families. The research will support Germany's efforts to integrate genomic medicine into standard patient care and advance understanding of rare diseases, developmental delay, and cancer.

PacBio (NASDAQ: PACB), a top developer of high-quality sequencing solutions, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 5, at 1:05 p.m. Eastern Time.

The event will be live-streamed on PacBio's investors page at investor.pacificbiosciences.com. For those unable to attend live, a replay will be available for at least 30 days following the event. This presentation offers investors and interested parties an opportunity to gain insights into PacBio's latest developments and future prospects in the sequencing technology sector.

PacBio (NASDAQ: PACB) reported Q2 2024 financial results with revenue of $36.0 million, down from $47.6 million in Q2 2023. The company faced headwinds in the capital equipment market, particularly in Europe and Asia. Key highlights include:

- Instrument revenue: $14.7 million (24 Revio™ systems sold)
- Consumables revenue: $17.0 million
- Service and other revenue: $4.3 million
- Net loss: $173.3 million ($0.64 per share)
- Non-GAAP net loss: $55.2 million ($0.20 per share)

Despite challenges, PacBio sees positive developments in population genomics programs and increasing adoption of Revio in clinical research. The company remains on track to reduce annual run rate expenses by over $75 million while maintaining key product development programs.

PacBio (NASDAQ: PACB) has partnered with Singapore's National Precision Medicine (NPM) programme to advance HiFi Sequencing in Southeast Asia. Precision Health Research, Singapore (PRECISE) has selected PacBio's Revio HiFi sequencing system for its Long-Read Sequencing Flagship Project, aiming to create the largest long-read sequencing dataset in the region. This collaboration will provide insights into genetic diversity, disease mechanisms, and clinical diagnoses within Singapore's multi-ethnic population.

The project includes:

• 60x HiFi depth for Pan-Asian reference genomes
• 20x HiFi depth for multi-omics analysis
• 30x HiFi depth for cancer and rare disease cases

PacBio will establish advanced sequencing infrastructure in Singapore, with Macrogen Asia Pacific Pte as the appointed service provider. The partnership leverages AWS cloud storage for secure data processing and access.